Recombinant CD38 (Daratumumab Biosimilar) antibody

Catalog No. ABIN7795093

This anti-CD38 (Daratumumab Biosimilar) antibody is a Mouse Monoclonal antibody detecting CD38 (Daratumumab Biosimilar) in FACS and in vivo. Suitable for Human.

Quick Overview for Recombinant CD38 (Daratumumab Biosimilar) antibody (ABIN7795093)

Target: CD38 (Daratumumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD38 (Daratumumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD38 (Daratumumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Daratumumab Biosimilar, CD38 Monoclonal Antibody

Characteristics: Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab. Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD38

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD38 (Daratumumab Biosimilar)

Target: CD38 (Daratumumab Biosimilar)

Alternative Name: Daratumumab Biosimilar

Target Type: Biosimilar